P

Inventor

PULÉ MARTIN

GB69 patents
⚠️ This page may combine multiple inventors who share the name “PULÉ MARTIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

AUTOLUS LTD

36 patents
US11091532B2Aug 17, 2021

T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptor

AUTOLUS LTD8 citations84
US11034750B2Jun 15, 2021

Chimeric antigen receptor (CAR) comprising a CD19-binding domain

AUTOLUS LTD8 citations84
US10981970B2Apr 20, 2021

Chimeric antigen receptor (CAR) comprising a CD22-binding domain

AUTOLUS LTD4 citations84
US10800855B2Oct 13, 2020

Chimeric cytokine receptors and encoding nucleic acids

AUTOLUS LTD4 citations83
US10800854B2Oct 13, 2020

Chimeric cytokine receptors and encoding nucleic acids

AUTOLUS LTD6 citations83
US10954530B2Mar 23, 2021

Retroviral and lentiviral vectors

AUTOLUS LTD5 citations82
US12187769B2Jan 7, 2025

Cell

AUTOLUS LTD2 citations74
US11058722B2Jul 13, 2021

Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domain

AUTOLUS LTD4 citations73
US11851672B2Dec 26, 2023

CAR T-cells comprising transcriptional circuits

AUTOLUS LTD3 citations72
US11479613B2Oct 25, 2022

Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins

AUTOLUS LTD1 citations72
US11365262B2Jun 21, 2022

Cell

AUTOLUS LTD4 citations72
US12049510B2Jul 30, 2024

Chimeric antigen receptor

AUTOLUS LTD2 citations71
US11590170B2Feb 28, 2023

Chimeric antigen receptor

AUTOLUS LTD3 citations71
US11180553B2Nov 23, 2021

Chimeric antigen receptor

AUTOLUS LTD4 citations71
US11466070B2Oct 11, 2022

Signalling system

AUTOLUS LTD2 citations69
US10919951B2Feb 16, 2021

Chimeric antigen receptor

AUTOLUS LTD2 citations69
US11103532B2Aug 31, 2021

Chimeric protein

AUTOLUS LTD2 citations68
US12398194B2Aug 26, 2025

Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface

AUTOLUS LTD0 citations62
US12234295B2Feb 25, 2025

Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof

AUTOLUS LTD0 citations62
US11959084B2Apr 16, 2024

Nucleic acid construct

AUTOLUS LTD1 citations62
US11879016B2Jan 23, 2024

Chimeric antigen receptor

AUTOLUS LTD0 citations62
US11701386B2Jul 18, 2023

Cell

AUTOLUS LTD1 citations62
US11648274B2May 16, 2023

Polypeptide

AUTOLUS LTD0 citations62
US11479614B2Oct 25, 2022

Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors

AUTOLUS LTD0 citations62
US11242377B2Feb 8, 2022

Chimeric receptor with ligand binding exodomain and cytokine and T cell signalling endodomains

AUTOLUS LTD1 citations62
US10975162B2Apr 13, 2021

Chimeric antigen receptor

AUTOLUS LTD1 citations62
US12454578B2Oct 28, 2025

Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors

AUTOLUS LTD0 citations61
US11345734B2May 31, 2022

Chimeric T cell

AUTOLUS LTD1 citations61
US11982672B2May 14, 2024

Methods

AUTOLUS LTD0 citations60
US11982673B2May 14, 2024

Methods

AUTOLUS LTD0 citations60
US11963981B2Apr 23, 2024

Chimeric antigen receptor

AUTOLUS LTD0 citations60
US11885807B2Jan 30, 2024

Method for depleting malignant T-cells

AUTOLUS LTD0 citations60
US11885806B2Jan 30, 2024

Method for depleting malignant T-cells

AUTOLUS LTD0 citations60
US11814641B2Nov 14, 2023

Retroviral and lentiviral vectors

AUTOLUS LTD0 citations60
US11385233B2Jul 12, 2022

Methods of depleting malignant T-cells

AUTOLUS LTD1 citations60
US12492410B2Dec 9, 2025

Engineered cytolytic immunecell

AUTOLUS LTD0 citations59

UCL BUSINESS PLC

11 patents

UCL BUSINESS LTD

3 patents

Showing the top 50 of 69 patents by PatentIndex Score.